Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
about
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancerSwitch in FOXA1 status associates with endometrial cancer progressionEnhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancerPrognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biologyAndrogen receptor as potential therapeutic target in metastatic endometrial cancer.Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.Prognostic biomarkers in endometrial and ovarian carcinoma.Current status of molecular biomarkers in endometrial cancer.PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients.Towards individualisation of treatment in endometrial cancer.Expression of SCUBE2 gene declines in high grade endometrial cancer and associates with expression of steroid hormone receptors and tumor suppressor PTEN.Expression Pattern of G-Protein-Coupled Estrogen Receptor in Myometrium of Uteri with and without Adenomyosis.HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach.
P2860
Q27852937-5D76BA0B-7CCF-4A7A-BEF3-E3B8E0E88D7CQ33645463-2DC849B8-BCE6-4A02-B6C3-31B4362B892AQ34526893-F954FCC3-BF24-43EA-8DCB-30DD404C5D03Q35879733-9DA7C265-3E30-4612-9278-E486D620CF31Q36096004-851635DE-24CE-4F34-ADEF-40074EBE9766Q36414073-031A71D4-FD2A-4951-9C1B-E1C964FCE0B2Q36451726-622B3EF9-B69D-45F4-8500-5046AC0DC48DQ37381777-DC8004EB-0867-4C2F-9D59-DA9A92393806Q37580217-B89341C9-A062-4D24-AD06-450632F10A72Q37706048-DB6FC5E5-4644-4BE7-8F18-FA02B5ACE17BQ38185940-4797B61E-FCE5-4DE3-AB59-4FCEB358908EQ38234228-6779B8E8-D1D1-4488-9FD7-0F12060BB294Q38599066-490E4071-1331-4C57-954D-AD9A5E67AE2AQ40104862-88C99C1C-1E58-437F-9F71-533DD3A1D6E5Q43168106-789E0924-37A8-40D9-A13E-CB65A987CA04Q45042162-6B31D2FE-BBAA-4653-8E88-5D58979F36F8Q47150383-EDFC5ED8-D6A6-4992-ADE3-E85EFAED6CC7Q47370686-E92EFA77-26B9-4220-8980-D521CD26C3CEQ48291376-26F65AEC-F666-4E5C-90FD-8D05CD259D6B
P2860
Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Loss of GPER identifies new ta ...... cer patients with poor outcome
@ast
Loss of GPER identifies new ta ...... cer patients with poor outcome
@en
type
label
Loss of GPER identifies new ta ...... cer patients with poor outcome
@ast
Loss of GPER identifies new ta ...... cer patients with poor outcome
@en
prefLabel
Loss of GPER identifies new ta ...... cer patients with poor outcome
@ast
Loss of GPER identifies new ta ...... cer patients with poor outcome
@en
P2093
P2860
P50
P356
P1476
Loss of GPER identifies new ta ...... cer patients with poor outcome
@en
P2093
E Birkeland
H B Salvesen
H M J Werner
I B Engelsen
I M Stefansson
K H Kalland
M B Raeder
P2860
P2888
P304
P356
10.1038/BJC.2012.91
P407
P577
2012-03-13T00:00:00Z
P5875
P6179
1018199884